USR-VS: a web server for large-scale prospective virtual screening using ultrafast shape recognition techniques.
Ligand-based Virtual Screening (VS) methods aim at identifying molecules with a similar activity profile across phenotypic and macromolecular targets to that of a query molecule used as search template. VS using 3D similarity methods have the advantage of biasing this search toward active molecules with innovative chemical scaffolds, which are highly sought after in drug design to provide novel leads with improved properties over the query molecule (e.g. patentable, of lower toxicity or increased potency). Ultrafast Shape Recognition (USR) has demonstrated excellent performance in the discovery of molecules with previously-unknown phenotypic or target activity, with retrospective studies suggesting that its pharmacophoric extension (USRCAT) should obtain even better hit rates once it is used prospectively. Here we present USR-VS (http://usr.marseille.inserm.fr/), the first web server using these two validated ligand-based 3D methods for large-scale prospective VS. In about 2 s, 93.9 million 3D conformers, expanded from 23.1 million purchasable molecules, are screened and the 100 most similar molecules among them in terms of 3D shape and pharmacophoric properties are shown. USR-VS functionality also provides interactive visualization of the similarity of the query molecule against the hit molecules as well as vendor information to purchase selected hits in order to be experimentally tested.
Institute of Future Cities, Chinese University of Hong Kong, Hong Kong.
Hongjian
H
Li
Department of Computer Science and Engineering, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.
Kwong-S
KS
Leung
Department of Computer Science and Engineering, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.
Man-H
MH
Wong
Cancer Research Center of Marseille, INSERM U1068, 13009-Marseille, France pedro.ballester@inserm.fr.
Pedro J
PJ
Ballester
D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005484:Fluspirilene / Q000737:chemistry; D007211:Indoles / Q000737:chemistry; D020407:Internet; D008024:Ligands; D004364:Pharmaceutical Preparations / Q000032:analysis* / Q000737:chemistry*; D015203:Reproducibility of Results; D012984:Software; D013449:Sulfonamides / Q000737:chemistry; D000077484:Vemurafenib
D007211:Indoles; D008024:Ligands; D004364:Pharmaceutical Preparations; D013449:Sulfonamides; D000077484:Vemurafenib; D005484:Fluspirilene